|
US9732131B2
(en)
|
2006-02-27 |
2017-08-15 |
Calviri, Inc. |
Identification and use of novopeptides for the treatment of cancer
|
|
EP4098278A1
(en)
|
2014-11-13 |
2022-12-07 |
The Johns Hopkins University |
Checkpoint blockade and microsatellite instability
|
|
MA40737A
(fr)
*
|
2014-11-21 |
2017-07-04 |
Memorial Sloan Kettering Cancer Center |
Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
|
|
WO2016146143A1
(en)
|
2015-03-16 |
2016-09-22 |
Amal Therapeutics Sa |
Cell penetrating peptides and complexes comprising the same
|
|
WO2016164833A1
(en)
|
2015-04-08 |
2016-10-13 |
Nantomics, Llc |
Cancer neoepitopes
|
|
RU2719033C2
(ru)
*
|
2015-04-23 |
2020-04-16 |
Нантомикс, Ллс |
Способ получения фармацевтического агента для иммунотерапии рака
|
|
EP3294324A1
(en)
|
2015-05-13 |
2018-03-21 |
Agenus Inc. |
Vaccines for treatment and prevention of cancer
|
|
GB201516047D0
(en)
*
|
2015-09-10 |
2015-10-28 |
Cancer Rec Tech Ltd |
Method
|
|
AU2016339924B2
(en)
*
|
2015-10-12 |
2020-01-02 |
Nantomics, Llc |
Compositions and methods for viral cancer neoepitopes
|
|
CA3003251A1
(en)
*
|
2015-10-12 |
2017-04-20 |
Nantomics, Llc |
Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
|
|
EP3362929B1
(en)
|
2015-10-12 |
2020-08-12 |
Nantomics, LLC |
Viral neoepitopes and uses thereof
|
|
CN108348588B
(zh)
*
|
2015-10-23 |
2023-01-13 |
诺华股份有限公司 |
用于导出视野中呈现的选定细胞的生物标志物阳性百分比值的方法
|
|
TWI733719B
(zh)
|
2015-12-07 |
2021-07-21 |
美商河谷控股Ｉｐ有限責任公司 |
改善的組合物及用於新表位之病毒遞送的方法及其應用
|
|
KR102883915B1
(ko)
|
2015-12-16 |
2025-11-18 |
시애틀 프로젝트 코포레이션 |
신생항원 동정, 제조, 및 용도
|
|
WO2017118702A1
(en)
*
|
2016-01-08 |
2017-07-13 |
Vaccibody As |
Neoepitope rna cancer vaccine
|
|
JP2019511903A
(ja)
|
2016-02-19 |
2019-05-09 |
ナント ホールディングス アイピー エルエルシーＮａｎｔ Ｈｏｌｄｉｎｇｓ ＩＰ， ＬＬＣ |
免疫原性調節の方法
|
|
CN109196121B
(zh)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
|
CN109476731A
(zh)
*
|
2016-02-29 |
2019-03-15 |
基础医药有限公司 |
治疗癌症的方法
|
|
CN109072227A
(zh)
|
2016-03-15 |
2018-12-21 |
组库创世纪株式会社 |
用于免疫治疗的监测和诊断及治疗剂的设计
|
|
PT3429618T
(pt)
*
|
2016-03-16 |
2024-04-02 |
Amal Therapeutics Sa |
Combinação de um modulador de ponto de controlo imunitário e um complexo que compreende um péptido de penetração celular, uma carga e um agonistra peptídico de tlr para utilização em medicina
|
|
KR20190017950A
(ko)
*
|
2016-06-10 |
2019-02-20 |
아이오 테라퓨틱스, 인크. |
암 면역요법을 위한 수용체 선택적 레티노이드 및 렉시노이드 화합물 및 면역 조절제
|
|
US20190247435A1
(en)
*
|
2016-06-29 |
2019-08-15 |
The Johns Hopkins University |
Neoantigens as targets for immunotherapy
|
|
IL265479B
(en)
|
2016-09-21 |
2022-09-01 |
Amal Therapeutics Sa |
A fusion containing a cell-penetrating peptide, a multiple epitope, and a peptide tlr agonist for cancer therapy
|
|
EP3516081A4
(en)
*
|
2016-09-23 |
2020-07-29 |
Memorial Sloan Kettering Cancer Center |
DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY
|
|
EP3523451A1
(en)
*
|
2016-10-06 |
2019-08-14 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
EP3548897A4
(en)
|
2016-12-01 |
2020-08-12 |
Nantomics, LLC |
PRESENTATION AND TREATMENT OF TUMOR ANTIGENICITY
|
|
WO2018112449A2
(en)
|
2016-12-16 |
2018-06-21 |
Nant Holdings Ip, Llc |
Live cell imaging systems and methods to validate triggering of immune response
|
|
US20190369096A1
(en)
*
|
2017-01-13 |
2019-12-05 |
Nantbio, Inc. |
Validation of neoepitope-based treatment
|
|
CA3050109A1
(en)
|
2017-01-18 |
2018-07-26 |
Ichan School Of Medicine At Mount Sinai |
Neoantigens and uses thereof for treating cancer
|
|
WO2018146128A1
(en)
*
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
|
|
AU2018234821A1
(en)
*
|
2017-03-17 |
2019-09-26 |
Nantomics, Llc |
Liquid biopsy for cfRNA
|
|
WO2018183928A1
(en)
*
|
2017-03-31 |
2018-10-04 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
EP3631471A4
(en)
|
2017-05-30 |
2021-06-30 |
Nant Holdings IP, LLC |
Circulating tumor cell enrichment using neoepitopes
|
|
CN110996970A
(zh)
|
2017-06-02 |
2020-04-10 |
亚利桑那州立大学董事会 |
创建个性化癌症疫苗的方法
|
|
US11322226B2
(en)
*
|
2017-06-13 |
2022-05-03 |
Bostongene Corporation |
Systems and methods for generating, visualizing and classifying molecular functional profiles
|
|
GB201710815D0
(en)
*
|
2017-07-05 |
2017-08-16 |
Francis Crick Inst Ltd |
Method
|
|
US12025615B2
(en)
|
2017-09-15 |
2024-07-02 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods of classifying response to immunotherapy for cancer
|
|
KR20200059243A
(ko)
|
2017-09-20 |
2020-05-28 |
리제너론 파마슈티칼스 인코포레이티드 |
패신저 유전자 돌연변이 부담이 높은 종양을 가진 환자에 대한 면역 치료요법
|
|
US12474340B2
(en)
|
2017-09-25 |
2025-11-18 |
Nant Holdings Ip, Llc |
Validation of neoepitope presentation
|
|
AU2018338441B2
(en)
*
|
2017-09-25 |
2025-08-14 |
Memorial Sloan Kettering Cancer Center |
Tumor mutational load and checkpoint immunotherapy
|
|
WO2019075112A1
(en)
|
2017-10-10 |
2019-04-18 |
Gritstone Oncology, Inc. |
IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
|
|
WO2019075468A1
(en)
|
2017-10-15 |
2019-04-18 |
Bristol-Myers Squibb Company |
TUMOR TREATMENT METHODS
|
|
WO2019090156A1
(en)
|
2017-11-03 |
2019-05-09 |
Guardant Health, Inc. |
Normalizing tumor mutation burden
|
|
CN111566484A
(zh)
*
|
2017-11-09 |
2020-08-21 |
宾夕法尼亚大学董事会 |
细胞外囊泡蛋白及其在癌症诊断、预测对疗法的反应和治疗中的用途
|
|
KR20260008173A
(ko)
|
2017-11-22 |
2026-01-15 |
시애틀 프로젝트 코포레이션 |
신생항원에 대한 접합 에피토프 제시 감소
|
|
EP3622522A1
(en)
|
2017-12-01 |
2020-03-18 |
Illumina, Inc. |
Methods and systems for determining somatic mutation clonality
|
|
CN108009400B
(zh)
*
|
2018-01-11 |
2018-07-06 |
至本医疗科技（上海）有限公司 |
全基因组肿瘤突变负荷预测方法、设备以及存储介质
|
|
US11414698B2
(en)
*
|
2018-03-22 |
2022-08-16 |
Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi |
Method of quantifying mutant allele burden of target gene
|
|
KR20210005646A
(ko)
|
2018-04-26 |
2021-01-14 |
아게누스 인코포레이티드 |
열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
|
|
AU2019310041B2
(en)
|
2018-07-23 |
2025-11-20 |
Guardant Health, Inc. |
Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
|
|
SG11202101400UA
(en)
|
2018-08-31 |
2021-03-30 |
Guardant Health Inc |
Microsatellite instability detection in cell-free dna
|
|
CN109371005B
(zh)
*
|
2018-11-12 |
2022-09-30 |
上海市东方医院（同济大学附属东方医院） |
一种hla-0201限制性padi4表位多肽及其应用
|
|
CN113194995A
(zh)
*
|
2018-12-12 |
2021-07-30 |
免疫医疗有限责任公司 |
基于血液的肿瘤突变负荷预测非小细胞肺癌的总存活
|
|
EP3899019A4
(en)
*
|
2018-12-21 |
2022-10-05 |
Agency for Science, Technology and Research |
METHOD OF PREDICTING THE BENEFITS OF IMMUNE CHECKPOINT INHIBITION THERAPY
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
WO2020206127A1
(en)
|
2019-04-05 |
2020-10-08 |
Illumina, Inc. |
Quantitative score of hla diversity
|
|
JP2022533480A
(ja)
*
|
2019-05-24 |
2022-07-22 |
エディフィス ヘルス，インコーポレーテッド |
癌免疫療法のためのプレシジョンメディシン法
|
|
EP4038222A4
(en)
|
2019-10-02 |
2023-10-18 |
Arizona Board of Regents on behalf of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
|
NL2024107B1
(en)
*
|
2019-10-26 |
2021-07-19 |
Vitroscan B V |
Compositions for Patient Specific Immunotherapy
|
|
CN111088349B
(zh)
*
|
2020-02-14 |
2023-04-28 |
深圳市宝安区妇幼保健院 |
Kir3dl1基因分型引物组及其应用
|
|
EP4127243B1
(en)
*
|
2020-03-23 |
2023-11-22 |
Koninklijke Philips N.V. |
Prediction of radiotherapy response for prostate cancer subject based on immune checkpoint genes
|
|
GB202007099D0
(en)
|
2020-05-14 |
2020-07-01 |
Kymab Ltd |
Tumour biomarkers for immunotherapy
|
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
EP4000596A1
(en)
*
|
2020-11-17 |
2022-05-25 |
The Boots Company plc |
Tetrapeptide and compositions comprising tetrapeptides
|
|
EP4000595A1
(en)
*
|
2020-11-17 |
2022-05-25 |
The Boots Company plc |
Tetrapeptide and compositions comprising tetrapeptides
|
|
US20240192195A1
(en)
*
|
2021-04-10 |
2024-06-13 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
A multiomic approach to modeling of gene regulatory networks in multiple myeloma
|
|
EP4392140A1
(en)
|
2021-08-24 |
2024-07-03 |
BioNTech SE |
In vitro transcription technologies
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
CN122003713A
(zh)
|
2023-04-12 |
2026-05-08 |
西奈山伊坎医学院 |
用于选择个性化新抗原疫苗的计算方法
|